Neurotoxicity Research

, Volume 23, Issue 1, pp 39–48 | Cite as

Neonatal DSP-4 Treatment Modifies Antinociceptive Effects of the CB1 Receptor Agonist Methanandamide in Adult Rats

  • Eva Korossy-Mruk
  • Katarzyna Kuter
  • Przemysław NowakEmail author
  • Ryszard Szkilnik
  • Monika Rykaczewska-Czerwinska
  • Richard M. Kostrzewa
  • Ryszard Brus
Open Access
Original Article


To study the influence of the central noradrenergic system on antinociceptive effects mediated by the CB1-receptor agonist methanandamide, intact rats were contrasted with rats in which noradrenergic nerves were largely destroyed shortly after birth with the neurotoxin DSP-4 [N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (50 mg/kg sc × 2, P1 and P3); zimelidine (10 mg/kg sc, 30 min pretreatment, selective serotonin reuptake inhibitor). When rats attained 10 weeks of age, monoamine and their metabolite concentrations were determined in the frontal cortex, thalamus, and spinal cord by an HPLC/ED method. Antinociceptive effects after methanandamide (10 mg/kg ip) apply were evaluated by a battery of tests. In addition, immunohistochemistry and densitometric analysis of the cannabinoid CB1 receptor in the rat brain was performed. DSP-4 lesioning was associated with a reduction in norepinephrine content of the frontal cortex (>90 %) and spinal cord (>80 %) with no changes in the thalamus. Neonatal DSP-4 treatment produced a significant reduction in the antinociceptive effect of methanandamide in the tail-immersion test, hot-plate test and writhing tests. In the paw pressure and formalin hind paw tests results were ambiguous. These findings indicate that the noradrenergic system exerts a prominent influence on analgesia acting via the cannabinoid system in brain, without directly altering CB1 receptor density in the brain.


Noradrenergic Lesion CB1 receptor Antinociception Rats 


Cannabinoids exert palliative effects in cancer patients by stimulating appetite and by abating nausea, vomiting, and pain. To date, cannabinoids have been licensed for clinical use as palliative treatment of chemotherapy, but increased evidence indicates a direct antiproliferative action of these drugs on several tumor cell lines, both in vitro and in animal models (Walsh et al. 2003). Also, recent evidence suggests that the endocannabinoid system mediates stress responses and regulates emotional homeostasis, in part, by targeting noradrenergic circuits. Simultaneously, the midbrain locus coeruleus (LC), that contains most noradrenergic neurons and projects to multiple cortical, limbic and autonomic-related brain structures, regulates arousal, attention, vigilance, stress, and pain (Berridge and Waterhouse 2003; Dunn et al. 2004). Alteration of norepinephrine (NE) exocytosis in the thalamus, brain stem and other nuclei alters output of nociceptive information to higher brain centers from projection neurons. Also, LC stimulation, which increases NE release in spinal cord, inhibits nociceptive transmission in the dorsal horn via α2-adrenergic receptors (Cenci et al. 1992; Delaney et al. 2007). Clinical evidence indicates a link between NE with pain modulation and opioid withdrawal syndrome. Abrupt cessation of opioid intake precipitates opioid withdrawal, which produces several aversive responses and symptoms, i.e., an abnormal increase in pain sensitivity (hyperalgesia) (Van Bockstaele et al. 2008).

LC activity is tightly controlled by presynaptic α2 autoreceptors (Lichtman and Martin 1991; Pudovkina and Westerink 2005) and by afferent pathways from several brain areas (Lee et al. 2005). Among these, serotonin (5-HT) and γ-aminobutyric acid (GABA)-containing neurons appear to play a major role (Aston-Jones et al. 1991). LC neurons possess a high density of postsynaptic mu-opioid receptors (Van Bockstaele and Commons 2001); and cannabinoids modulate noradrenergic neuronal activity. Scavone et al. (2010) provided evidence for a heterogeneous distribution of CB1 receptors in the LC and demonstrated that this receptor and mu-opioid receptors co-exist in cellular profiles in this region. Others have shown an interaction between the cannabinoid system and the NE system in areas such as the prefrontal cortex (Oropeza et al. 2007), nucleus accumbens (Carvalho et al. 2010) and the nucleus of the solitary tract (Jelsing et al. 2009).

Previously, we showed that N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4; 50 mg/kg sc per day), administered on the 1st and 3rd days of postnatal life, alters noradrenergic input to the hippocampus and prefrontal cortex (endogenous NE content was reduced by 98.5 and 95.0 %, respectively), without impairing dopaminergic and serotoninergic input to these regions. An elevated NE level was found in brainstem and cerebellum of these DSP-4-treated rats, suggestive of reactive neuronal sprouting (Brus et al. 2004; Nowak et al. 2006; Dąbrowska et al. 2007). In addition, we reported that neonatal DSP-4 treatment modifies convulsant effects of bicuculine and pentetrazole, as well as sensitivity to the anxiolytic-like effect of benzodiazepines, and the sedative-hypnotic effect of phenobarbital and ethanol in adult rats (Bortel et al. 2007, 2008a, b). And we established that the GABA transaminase inhibitor vigabatrin causes a twofold increase in the extracellular GABA concentration in DSP-4-lesioned rat brain (Bortel et al. 2008c). In the present study, a lesion of noradrenergic neurons was made in early postnatal ontogeny, in order to assess how subsequent postnatal compensatory processes influence cannabinoid-induced antinociception. This phenomenon may be of importance, because adrenergic receptor dysfunction is suspect in patients with clinical depression, anxiety disorder and other neuropsychiatric disorders (Ressler and Nemeroff 1999; Anand and Charney 2000) and neurological disease (Parkinson’s and Alzheimer’s disease) (Narabayashi 1999; Haglund et al. 2006). Furthermore, the difficulties of relieving painful symptoms associated with some pathological entities, i.e., bone cancer pain, justify experimental efforts to define new analgesic targets. Cannabinoid CB1 receptor agonists represent a class with this desired analgesic potential (Farquhar-Smith 2009).

Materials and Methods

Animals and Treatment

Wistar rats (University Animal Department, Katowice, Poland) were housed under controlled environmental conditions, in a well-ventilated room, at 22 ± 2 °C and under a 12 h light:12 h dark cycle (lights on from 7:00 a.m. to 7:00 p.m.). Animals received food and water ad libitum. Litters remained with dams until the 21st day after birth and then were placed in individual cages according to sex. Experiments were carried out in the morning in only male rats, handled in accordance with the principles and guidelines described in the NIH Guide for the Care and Use of Laboratory Animals. All procedures were reviewed and approved by the Local Bioethical Committee for Animal Care at the Medical University of Silesia (decision no. 49/2009 issued on 17.06.2009).

The central noradrenergic system of newborn rats was lesioned with DSP-4 (Sigma, St. Louis, MO, USA). Rats were injected on the 1st and 3rd day of postnatal life with either DSP-4 (50 mg/kg sc) or 0.9 % NaCl (1.0 ml/kg sc). DSP-4 was dissolved in distilled water immediately before injection, and preceded 30 min beforehand by treatment with the selective serotonin reuptake inhibitor zimelidine (10 mg/kg ip) (Sigma, St. Louis, MO, USA)—in order to prevent serotoninergic effects of DSP-4. The dose and the days of treatment were selected on the basis of the reports by Jonsson et al. (1982), Brus et al. (2004) and Dąbrowska et al. (2007). Rats continued to be housed as above until 10 weeks, for further experimentation.

Assessment of Biogenic Amine and Metabolite Content

At 10 weeks after birth control and DSP-4-treated rats were injected with saline (1.0 ml/kg ip) or methanandamide (10 mg/kg ip) (Tocris Bioscience, Ellisville, MO, USA), and were terminated by decapitation 60 min later. The frontal cortex, thalamus, and spinal cord were rapidly dissected and placed on dry ice, weighed and stored at −70 °C, pending assay. Samples were homogenized for 15–20 s in ice-cold trichloracetic acid (0.1 M), containing 0.05 mM ascorbic acid. After centrifugation (5,000×g, 5 min), supernatants were filtered through 0.2 μm cellulose membranes (Titan MSF Microspin filters, Scientific Resources Inc., Eatontown GB) and filtrates were injected onto the HPLC/ED column. Levels of NE, dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) were assayed by HPLC/ED (Nowak et al. 2003). The composition of the mobile phase was: 75 mM NaH2PO4, 1.7 mM 1-octanesulfonic acid, 5 μM EDTA (Avocado, Research Chemical Ltd., Morecambe, GB), 100 μl triethylamine (Sigma, St. Louis, USA), 9.5 % acetonitrile (J.T. Baker, Deventer, Holland), pH 3 adjusted with phosphoric acid (Fluka, Steinheim, Switzerland). The flow rate was maintained at 0.7 ml/min, at a temperature of 22 °C, and the oxidation potential was fixed at +700 mV, 10 nA/V sensitivity. Peaks were automatically integrated by universal chromatographic interface UCI-100 (Dionex Softron Gmbh, Germering, Germany). The instrumentation included an electrochemical detector (Gilson, Villiers-le-Bel, France) model 141 with flow cell, piston pump model 302 with head 5SC (Gilson, Villiers-le-Bel, France), manometric module model 802 (Gilson, Villiers-le-Bel, France), thermostat for STH 595 column (Dionex Softron Gmbh, Germering, Germany), precolumn Hypersil BDS C18, 10 × 4 mm, 3 μm (ThermoQuest, Waltham, GB), and chromatographic column Hypersil BDS C18, 250 × 4.6 mm, 3 μm (ThermoQuest, Waltham, GB). The data were quantified using the area under the peaks and external standards, using Chromeleon software (Dionex, Germany).

Immunohistochemistry and Densitometric Analysis

Immunostaining for CB1 receptor expression was carried out according to Kuter et al. (2011). At 10 weeks after birth control and DSP-4-treated rats were decapitated. The brains were rapidly removed, postfixed in cold 4 % paraformaldehyde for 7 days and cryoprotected in 20 % sucrose solution in phosphate-buffered saline (PBS). The brains were cut on a freezing microtome into 30 μm frontal sections (AP = 2.52 mm from bregma according to Paxinos and Watson 2007). Free-floating sections were incubated for 48 h at 4 °C in a primary antibodies (anti-CB1 receptor, 1: 1,000; Sigma, Germany), rinsed in PBS, then incubated for 30 min in secondary antibodies (anti rabbit biotinylated, 1:200, Vector Laboratories, UK) and processed using an ABC-peroxidase kit (Vector Laboratories, UK) and 3,3′-diaminobenzidine as a chromogen. The stained sections were mounted on slides, dried, dehydrated, cleared in xylene and cover-slipped in a Permount medium (Fisher Scientific, USA).

Two sections stained immunohistochemically for CB1 receptor were analyzed densitometrically in the region of striatum and frontal cortex. The sections were scanned all together, digitalized, adjusted for brightness, and regions of interest outlined using Multi Gauge programme (FUJIFILM). The optical density and area (OD) were counted. Background signal was subtracted from each section separately, from the region of corpus callosum. The results are presented as mean of each OD/area2 value minus backgrounds.

Tail-Immersion Test

Antinociception was evaluated by measuring response latencies in the warm water tail-immersion (tail-flick) assay (Janssen et al. 1963). Each animal was placed in a cone restrainer, and the caudal 2/3 of tails of rat was immersed 5 cm in a 56 °C water bath. The time for the rats to remove their tails from the water was expressed as the tail flick latency. A cut-off time of 10 s was used to minimize damage to the skin of the tail. Reaction latency (s) was used as a parameter reflecting the intensity of the pain experienced. The determined latency time for each animal was converted to the percentage of analgesia according to the formula:
$$ {\text{\% analgesia = }}\frac{{T_{\text{x}} - \, T_{0} }}{{T_{ \max } - \, T_{0} }} \times 100 $$
T x—the individual latency time determined at appropriate intervals after examined analgesics administration, T 0—individual latency time determined before analgesics injection, T max—10 s. The analgesic effect was measured before drug administration (after saline 1.0 ml/kg ip) and at 30, 60, 90, 120, and 150 min after methanandamide (10 mg/kg ip) injection.

Hot Plate

Antinociception was assessed according to O’Callaghan and Holtzman (1975) using a hot-plate instrument (COTM, Bialystok, Poland) with the plate temperature maintained at 56 ± 0.1 °C. The rat was placed with all four paws on the plate, and the latency time to licking or shaking a hind limb was measured. The cut-off time was set at 20 s to avoid tissue damage. The determined latency time for each animal was converted to the percentage of analgesia according to the formula:
$$ \% {\text{ analgesia }} = \frac{{T_{\text{x}} - \, T_{0} }}{{T_{ \max } - \, T_{0} }} \times 100 $$
T x—the individual latency time determined at appropriate intervals after examined analgesics administration, T 0—individual latency time determined before analgesics injection, T max—20 s. The analgesic effect was measured before drug administration (after saline 1.0 ml/kg ip) and at 10, 20, 30, 40, 50 and 60 min after methanandamide (10 mg/kg ip) injection.

Writhing Test

Control and DSP-4 rats (deprived of food 24 h before testing) were placed individually in clear plexiglas boxes (40 × 30 × 20 cm) and allowed to acclimate for 30 min. Rats were then injected with saline (1.0 ml/100 g ip) and 30 min later, treated with ethacrynic acid solution (3.0 mg/1 ml/100 g) in the left lower quadrant of the abdomen. Ethacrynic solution was prepared ex tempore in the proportion of 3/47 ethanol/water. Rat were returned to the chamber and 10 min later contractions of abdominal musculature (writhes) were counted (contractions of the abdomen, twisting and turning of the trunk, arching of the back and extension of the hind limbs) for the following 60 min with division on 10 min intervals (10–20, 20–30, 30–40, etc.). Rats were used once and then killed immediately (Korzeniewska-Rybicka and Płaźnik 2001). According to the same paradigm, separate groups of rats (control and DSP-4) were tested after methanandamide (10 mg/kg ip) treatment. The degree of antinociception was expressed as the percentage decrease in the number of writhes and was calculated according to the formula:
$$ {\text{\% inhibition of writhing = 100}} - \frac{100 \times B}{A} $$
A—the mean number of writhes in saline-treated control and DSP-4 rats for appropriate observation period; B—the mean number of writhes in drug-treated rats counted for appropriate observation interval.

Paw-Pressure Test

Nociceptive thresholds in rats were determined by a modification of the Randall–Selitto method (Randall and Selitto 1985), the paw-pressure vocalization test, in which a constantly increasing pressure is applied to the hind paw until the rat squeaks. The Ugo Basil analgesimeter (probe tip diameter 1 mm; weight 25 g) was used. A 750-g cutoff value was used for preventing tissue damage. In brief, a constantly increasing pressure was applied to the right hind paw of the rat at the metacarpal level between the third and the fourth finger to determine the minimum stimulus necessary to evoke an obvious nociceptive response (a sharp paw withdrawal). Rats were habituated to the full procedure on two consecutive days and experiments were conducted on the third day. To insure nociceptive threshold stability, basal nociceptive threshold was measured three times (with an interval of 30 min) on the 2 days before the planned experimental day. On the experimental day, basal nociceptive threshold was also determined three times before drug injections. The following formula was used to count the percentage of analgesia:
$$ \% {\text{ analgesia }} = \frac{100 \times B}{A} - 100 $$
A—mean pressure (g) from 3 assessments before drug administration; B—pressure (g) assessed at 30, 60, 90, 120 min after methanandamide (10 mg/kg ip) treatment.

Formalin Test

Inflammatory pain and analgesia were determined using the formalin test in the rat (Acton et al. 1992). Rats were placed in a clear plastic chamber (30 × 30 × 30 cm) for 30 min to allow them to accommodate to their surroundings with a mirror placed at a 45° angle beneath the floor to allow an unobstructed view of the paws. Then, 30 min after methanandamide (10 mg/kg ip) administration, 50 μl of 5 % formalin solution was injected subcutaneously, 30-gauge needle, into the right hind paw plantar surface. Rats were then returned to the chambers, and nociceptive behavior was observed immediately after formalin injection. Nociceptive behavior was quantified using the scale 0–3 points. Formalin-induced pain is biphasic. The initial acute phase (0–10 min) is followed by a relatively short quiescent period, which is then followed by a prolonged tonic response (15–60 min). A reduction of formalin-induced behavior observed after administration of a given drug is interpreted as an analgesic response.

Statistical Analysis

Group differences in monoamines were assessed by an analysis of variance (ANOVA) and the post-ANOVA test of Newman–Keuls. Group differences in behavioral studies were analyzed by Student’s t test. A P value <0.05 was taken as the level of significant difference.


Effect of DSP-4 Treatment on Monoamine Concentration in the Frontal Cortex, Thalamus, and Spinal Cord

In rats treated on the 1st and 3rd days of postnatal life with DSP-4 (50 mg/kg sc), and killed at 10 weeks, the adulthood level of NE in the frontal cortex and spinal cord either after saline or methanandamide (10 mg/kg ip) treatment was significantly decreased in comparison to the respective control. DA content in the frontal cortex was reduced in the DSP-4 group while DOPAC and HVA were reduced in spinal cord, versus control. The endogenous level of 5-HT and 5-HIAA in both structures remained unaltered (Fig. 1a, c).
Fig. 1

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on the content of monoamines and their metabolites in frontal cortex (a), thalamus (b) and spinal cord (c), following acute methanandamide (10 mg/kg ip) treatment of adult rats (x ± SEM; n = 6). Legend White square control, Light grey square DSP-4 control + methanandamide, Dark grey square DSP-4 + methanandamide, *P < 0.05, control versus DSP-4, # P < 0.05, control + methanandamide versus DSP-4 + methanandamide, ^P < 0.05, DSP-4 versus DSP-4 + methanandamide

In the thalamus methanandamide treatment significantly reduced NE, 5-HT and 5-HIAA concentration only in control rats, while there was no consisted change in DA and its metabolite DOPAC (Fig. 1b).

Immunohistochemistry and Densitometric Analysis for CB1 Receptor Expression

Immunostaining for CB1 receptor expression was carried out in the frontal cortex and striatum, showing no significant changes between control and DSP-4 rats in both structures (Fig. 2).
Fig. 2

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on CB1 receptor immunoreactivity, assessed densitometrically in brain slices in the frontal cortex and striatum of adult rats. a Results are shown as the mean ± SEM (n = 7 per group) in arbitrary units of optical density (OD). b Representative CB1 receptor immunostained sections at the level of the corpus striatum with delineation of subregions of the corpus striatum and frontal cortex. Background was assessed in the region (shown as a rectangle) of the corpus callosum. Legend White square control, Grey square DSP-4

Tail-Immersion Test

Methanandamide (10 mg/kg ip) evoked a lower antinociceptive effect in DSP-4 rats in comparison to control rats. Obtained differences were significant at 30, 60, and 90 min of testing (Fig. 3).
Fig. 3

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on antinociception effects assessed in the tail-immersion test after methanandamide (10 mg/kg ip) treatment in rats (mean ± SEM; n = 8). Legend White square control, Grey square DSP-4, *P < 0.05, control versus DSP-4

Hot-Plate Test

Methanandamide (10 mg/kg ip) elicited a lower antinociceptive effect in DSP-4 rats in comparison to control animals, and differences were significant at 10, 20, 30, 40, 50 an 60 min of observation (Fig. 4).
Fig. 4

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on antinociception effects assessed in the hot-plate test after methanandamide (10 mg/kg ip) treatment in rats (mean ± SEM; n = 8). Legend as in Fig. 3

Writhing Test

Injections of methanandamide (10 mg/kg ip) produced a lower antinociceptive effect in the DSP-4 group in comparison to control rats, and the effect was significant at 40–50, 50–60 and 60–70 intervals of observation (Fig. 5).
Fig. 5

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on antinociception effects assessed in the writhing test after methanandamide (10 mg/kg ip) treatment in rats (mean ± SEM; n = 8). Legend as in Fig. 3

Paw-Pressure Test

Prior to drug injection, withdrawal thresholds of intact and DSP-4 rats were 8.94 ± 1.36 and 9.03 ± 1.29 g, respectively (means from all measurements, n = 24 for each group). Methanandamide (10 mg/kg ip) elicited a narrowly lower antinociceptive effect in DSP-4 treated rats in comparison to control animals (significant difference only at 30 min of testing) (Fig. 6).
Fig. 6

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on antinociception effects assessed in the paw-pressure test after methanandamide (10 mg/kg ip) treatment in rats (mean ± SEM; n = 8). Legend as in Fig. 3

Formalin Test

To assess the effect of a neonatal noradrenergic lesion on adulthood analgesic action of methanandamide, a comparison of DSP-4 and control rats was made for the behavioral responses to sc injection of 50 μl (5 %) of formalin into a hind paw. Methanandamide (10 mg/kg ip) was administered 30 min before formalin application. Both groups showed the typical biphasic nociceptive response for the 60 min of testing, but DSP-4 lesioned rats scored fewer points (spending less time licking/biting the injected hind paw) in the first phase of the formalin test than the control group (P < 0.05 at 1 and 5 min), but in the remaining 50 min of observation the opposite effect was observed (Fig. 7).
Fig. 7

Effect of neonatal DSP-4 lesioning (50 mg/kg sc on the 1st and 3rd days of postnatal life) on antinociception effects assessed in the formalin test after methanandamide (10 mg/kg ip) treatment in rats (mean ± SEM; n = 8). Legend as in Fig. 3


The major finding of the present study is that neonatal DSP-4 treatment—resulting in permanent destruction of noradrenergic inputs to spinal cord and cortical areas—diminishes adulthood CB1-receptor agonist mediated antinoception, in the absence of change in CB1 receptor density in brain.

The antinociceptive effects of endocannabinoids have been well described in animal models of acute and chronic pain (Walker and Huang 2002). Cannabinoid analgesia involves effects at the supraspinal, spinal and peripheral levels (Agarwal et al. 2007; Hohmann and Suplita 2006). Furthermore, there is a large body of evidence associating the cannabinoid system with regulation of noradrenergic activity. Systemic administration of the synthetic cannabinoid agonist WIN 55,212-2 enhances NE release in prefrontal cortex and increases c-fos expression in the LC. In addition, there is a significant alteration in adrenergic receptor and NE transporter expression in the frontal cortex (Oropeza et al. 2005). McLaughlin et al. (2009) found that the acute administration of exogenous cannabinoid ligands activates the hypothalamic–pituitary–adrenal axis through an increase in serotoninergic and noradrenergic neurotransmission. All of the above may underlie the reported changes in attention, cognition, anxiety and pain threshold commonly observed after cannabinoid exposure (Reyes et al. 2009). Yet, there are no data regarding such an association in NE-denervated animals. Neonatal treatment with neurotoxins, such as 6-hydroxydopamine (6-OHDA) or DSP-4 produces marked impairment in development of the central noradrenergic system, i.e., permanent and robust NE-denervation of the frontal cortex and spinal cord (Fig. 1a, c), accompanied by NE hyperinnervation of brainstem and cerebellum (Jaim-Etcheverry and Zieher 1980; Medina and Novas 1983).

In the present study, destruction of noradrenergic neurons by DSP-4 significantly decreased the antinociceptive effect of methanandamide (10 mg/kg ip) in the tail-immersion test, hot-plate test, and writhing test (Figs. 3, 4, 5). Ambiguous results were obtained in the paw pressure and formalin tests (Figs. 6, 7). Despite marked antinociceptive effects of methanandamide, there was no change in CB1 receptor density in rat brain (Fig. 2). Gutierrez et al. (2003) demonstrated that intrathecal administration of 6-OHDA, resulting in selective 85 % NE depletion in rat lumbar spinal cord, attenuated the antinociceptive effect of the cannabinoid agonist WIN55,212-2 (5 or 10 mg/kg, ip) as assessed in the tail-flick and formalin tests. They also found that WIN55,212-2 suppressed formalin-evoked fos protein expression, a marker of neuronal activity, in the lumbar dorsal horn of sham-operated rats, while no suppression was observed in lesioned rats. Thus, cannabinoids produce antinociception, in part, by modulating descending noradrenergic systems. To the best of our knowledge there are no data relating to the analgesic effect of CB1 receptor agonists in neonatally DSP-4 treated rats. Kushikata et al. (2011) showed that DSP-4 (50 mg/kg ip in adult rats) significantly reduced ketamine analgesia in the hot-plate test. Others (Zhong et al. 1985) found that in rats pretreated intrathecally with DSP-4, the analgesic effect of morphine, given either icv or ip and assessed in a tail-flick test, was significantly attenuated.

Previous reports (Oropeza et al. 2005; Page et al. 2008) indicate that CB1 receptor agonists activate the noradrenergic pathway. Martin et al. (1999) reported that WIN55,212-2 elevated tail-flick latencies when injected into the noradrenergic A5 region. Yoon and Choi (2003) demonstrated synergistic interaction after intrathecal delivery of WIN 55,212-2 and clonidine in the formalin test. And, Tham et al. (2005) showed that an α2-adrenoceptor agonist (dexmedetomidine) when combined with a cannabinoid receptor agonist (CP55,940) resulted in a synergistic antinociceptive effect in the hot-plate test. Summing up, the above reports, plus results of the current study, indicate that a reduction in methanandamide induced analgesia may be attributable to destruction of noradrenergic neurons.

Nevertheless, we cannot definitely exclude participation of the 5-HT system in the obtained results, particularly considering the fact that Mendiguren and Pineda (2009) showed that anandamide inhibited 5-HT neuronal firing in rat brain slices of the dorsal raphe nucleus. Also, pain sensation is known to be modified by the serotoninergic system, another monoaminergic pathway. As already noted, DSP-4-induced NE depletion attenuated 5-HT ligand mediated analgesia (Minor et al. 1986; Archer et al. 1987). And in our study we found that in the thalamus methanandamide reduced 5-HT and 5-HIAA concentrations, although only in control rats. Therefore, it is quite possible that the serotoninergic system in particular and other phenotypic systems in general, may be influenced by DSP-4 lesioning of noradrenergic innervation and its effect on antinociception.

In conclusion, the present study demonstrates a prominent effect of noradrenergic neurons in regulating the antinociceptive effects of methanandamide—the CB1 receptor agonist—without altering CB1 receptor density in brain. The associated pathways involved in this effect remain to be resolved.


Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.


  1. Acton J, McKenna JE, Melzak R (1992) Amitriptyline produces analgesia in the formalin pain test. Exp Neurol 117:94–96PubMedCrossRefGoogle Scholar
  2. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870–879PubMedCrossRefGoogle Scholar
  3. Anand A, Charney DS (2000) Norepinephrine dysfunction in depression. J Clin Psychiatry 61:16–24PubMedCrossRefGoogle Scholar
  4. Archer T, Arweström E, Minor BG, Persson ML, Post C, Sundstrom E, Jonson G (1987) (+)-8-OH-DPAT and 5-MeODMT induced analgesia is antagonised by noradrenaline depletion. Physiol Behav 39:95–102PubMedCrossRefGoogle Scholar
  5. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R (1991) Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 88:47–75PubMedCrossRefGoogle Scholar
  6. Berridge CW, Waterhouse BD (2003) The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42:33–84PubMedCrossRefGoogle Scholar
  7. Bortel A, Świerszcz M, Jaksz M, Nitka D, Słomian L, Nowak P, Brus R (2007) Anxiety-like behaviour in neonatally DSP-4 treated rats. Behavioural and biochemical studies. Ann Acad Med Siles 61:485–491Google Scholar
  8. Bortel A, Nitka D, Słomian L, Nowak P, Korossy E, Brus R, Kostrzewa RM (2008a) Neonatal noradrenergic lesion with DSP-4 modifies the convulsant effect of bicuculine and pentylenetetrazole in adult rats. Behavioral and biochemical studies. Ann Acad Med Siles 62:46–52Google Scholar
  9. Bortel A, Nowak P, Brus R (2008b) Neonatal DSP-4 treatment modifies GABA-ergic neurotransmission in the prefrontal cortex of adult rats. Neurotox Res 13:247–252PubMedCrossRefGoogle Scholar
  10. Bortel A, Słomian L, Nitka D, Świreszcz M, Jaksz M, Adamus-Sitkiewicz B, Nowak P, Jośko J, Kostrzewa RM, Brus R (2008c) Neonatal N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) treatment modifies the vulnerability to phenobarbital- and ethanol-evoked sedative-hypnotic effects in adult rats. Pharmacol Rep 60:331–338PubMedGoogle Scholar
  11. Brus R, Nowak P, Labus Ł, Bortel A, Dąbrowska J, Kostrzewa RM (2004) Neonatal lesion of noradrenergic neurons in rat brain: interaction with the dopaminergic system. Pol J Pharmacol 56:232 (abstract)Google Scholar
  12. Carvalho AF, Mackie K, Van Bockstaele EJ (2010) Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci 31:286–301PubMedCrossRefGoogle Scholar
  13. Cenci MA, Kalén P, Mandel RJ, Björklund A (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res 581:217–228PubMedCrossRefGoogle Scholar
  14. Dąbrowska J, Nowak P, Brus R (2007) Desensitization of 5-HT(1A) autoreceptors induced by neonatal DSP-4 treatment. Eur Neuropsychopharmacol 17:129–137PubMedCrossRefGoogle Scholar
  15. Delaney AJ, Crane JW, Sah P (2007) Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron 56:880–892PubMedCrossRefGoogle Scholar
  16. Dunn AJ, Swiergiel AH, Palamarchouk V (2004) Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann NY Acad Sci 1018:25–34PubMedCrossRefGoogle Scholar
  17. Farquhar-Smith WP (2009) Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care 3:7–13PubMedCrossRefGoogle Scholar
  18. Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG (2003) Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res 987:176–185PubMedCrossRefGoogle Scholar
  19. Haglund M, Sjöbeck M, Englund E (2006) Locus ceruleus degeneration is ubiquitous in Alzheimer’s disease: possible implications for diagnosis and treatment. Neuropathology 26:528–532PubMedCrossRefGoogle Scholar
  20. Hohmann AG, Suplita RL (2006) Endocannabinoid mechanisms of pain modulation. AAPS J 8:E693–E708PubMedCrossRefGoogle Scholar
  21. Jaim-Etcheverry G, Zieher LM (1980) DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res 188:513–523PubMedCrossRefGoogle Scholar
  22. Janssen PA, Niemegeers CJE, Dony JGH (1963) The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneimittelforschung 13:502–507PubMedGoogle Scholar
  23. Jelsing J, Galzin AM, Guillot E, Pruniaux MP, Larsen PJ, Vrang N (2009) Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2. Brain Res Bull 78:202–210PubMedCrossRefGoogle Scholar
  24. Jonsson G, Hallman H, Sundstrom E (1982) Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat. Neuroscience 7:2895–2907PubMedCrossRefGoogle Scholar
  25. Korzeniewska-Rybicka I, Płaźnik A (2001) Role of serotonergic and noradrenergic systems in a model of visceral pain. Pol J Pharmacol 53:475–480PubMedGoogle Scholar
  26. Kushikata T, Yoshida H, Kudo M, Kudo T, Kudo T, Hirota K (2011) Role of coerulean noradrenergic neurones in general anaesthesia in rats. Br J Anaesth 107:924–929PubMedCrossRefGoogle Scholar
  27. Kuter K, Kolasiewicz W, Gołembiowska K, Dziubina A, Schulze G, Berghauzen K, Wardas J, Ossowska K (2011) Partial lesion of the dopaminergic innervation of the ventral striatum induces “depressive-like” behavior of rats. Pharmacol Rep 63:1383–1392PubMedGoogle Scholar
  28. Lee HS, Kim MA, Waterhouse BD (2005) Retrograde double-labeling study of common afferent projections to the dorsal raphe and the nuclear core of the locus coeruleus in the rat. J Comp Neurol 481:179–193PubMedCrossRefGoogle Scholar
  29. Lichtman AH, Martin BR (1991) Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 559:309–314PubMedCrossRefGoogle Scholar
  30. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822:237–242PubMedCrossRefGoogle Scholar
  31. McLaughlin RJ, Hill MN, Gorzalka BB (2009) Monoaminergic neurotransmission contributes to cannabinoid-induced activation of the hypothalamic–pituitary–adrenal axis. Eur J Pharmacol 624:71–76PubMedCrossRefGoogle Scholar
  32. Medina JH, Novas ML (1983) Parallel changes in brain flunitrazepam binding and density of noradrenergic innervation. Eur J Pharmacol 88:377–382PubMedCrossRefGoogle Scholar
  33. Mendiguren A, Pineda J (2009) Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. Br J Pharmacol 158:1579–1587PubMedCrossRefGoogle Scholar
  34. Minor BG, Archer T, Post C, Jonsson G, Mohammed AK (1986) 5-HT agonist induced analgesia modulated by central but not peripheral noradrenaline depletion in rats. J Neural Transm 66:243–259PubMedCrossRefGoogle Scholar
  35. Narabayashi H (1999) Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson’s disease. Adv Neurol 80:501–504PubMedGoogle Scholar
  36. Nowak P, Labus L, Stabryla J, Durczok A, Brus R, Nowicka J, Shani J (2003) Biogenic amines in striatum of rats that had been treated with ethanol, and their brains later stored in different temperatures. Recept Channels 9:339–342PubMedGoogle Scholar
  37. Nowak P, Labus Ł, Kostrzewa RM, Brus R (2006) DSP-4 prevents dopamine receptor priming by quinpirole. Pharmacol Biochem Behav 84:3–7PubMedCrossRefGoogle Scholar
  38. O’Callaghan JP, Holtzman SG (1975) Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J Pharmacol Exp Ther 192:497–505PubMedGoogle Scholar
  39. Oropeza VC, Page ME, Van Bockstaele EJ (2005) Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 1046:45–54PubMedCrossRefGoogle Scholar
  40. Oropeza VC, Mackie K, Van Bockstaele EJ (2007) Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 1127:36–44PubMedCrossRefGoogle Scholar
  41. Page ME, Oropeza VC, Van Bockstaele EJ (2008) Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 431:1–5PubMedCrossRefGoogle Scholar
  42. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, Sixth edition. Academic Press (Elsevier Inc.), AmsterdamGoogle Scholar
  43. Pudovkina OL, Westerink BH (2005) Functional role of alpha1-adrenoceptors in the locus coeruleus: a microdialysis study. Brain Res 1061:50–56PubMedCrossRefGoogle Scholar
  44. Randall LO, Selitto JJ (1985) A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn 61:409–419Google Scholar
  45. Ressler KJ, Nemeroff CB (1999) Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 46:1219–1233PubMedCrossRefGoogle Scholar
  46. Reyes BA, Rosario JC, Piana PM, Van Bockstaele EJ (2009) Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res 87:3671–3678PubMedCrossRefGoogle Scholar
  47. Scavone JL, Mackie K, Van Bockstaele EJ (2010) Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res 1312:18–31PubMedCrossRefGoogle Scholar
  48. Tham SM, Angus JA, Tudor EM, Wright CE (2005) Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 144:875–884PubMedCrossRefGoogle Scholar
  49. Van Bockstaele EJ, Commons KG (2001) Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience 108:467–477PubMedCrossRefGoogle Scholar
  50. Van Bockstaele EJ, Qian Y, Sterling RC, Page ME (2008) Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain. Prog Neuropsychopharmacol Biol Psychiatry 32:1048–1056PubMedCrossRefGoogle Scholar
  51. Walker JM, Huang SM (2002) Cannabinoid analgesia. Pharmacol Ther 95:127–135PubMedCrossRefGoogle Scholar
  52. Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11:137–143PubMedCrossRefGoogle Scholar
  53. Yoon MH, Choi JI (2003) Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 99:701–707PubMedCrossRefGoogle Scholar
  54. Zhong FX, Ji XQ, Tsou K (1985) Intrathecal DSP4 selectively depletes spinal noradrenaline and attenuates morphine analgesia. Eur J Pharmacol 116:327–330PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • Eva Korossy-Mruk
    • 1
  • Katarzyna Kuter
    • 2
  • Przemysław Nowak
    • 1
    • 3
    Email author
  • Ryszard Szkilnik
    • 4
  • Monika Rykaczewska-Czerwinska
    • 1
  • Richard M. Kostrzewa
    • 5
  • Ryszard Brus
    • 6
  1. 1.Chair and Department of PharmacologyMedical University of SilesiaZabrzePoland
  2. 2.Department of Neuro-Psychopharmacology, Institute of PharmacologyPolish Academy of SciencesKrakówPoland
  3. 3.Occupational Health Protection Unit, Public Health FacultyMedical University of SilesiaKatowice LigotaPoland
  4. 4.Department of Basic Medical SciencesMedical University of SilesiaBytomPoland
  5. 5.Department of Pharmacology, Quillen College of MedicineEast Tennessee State UniversityJohnson CityUSA
  6. 6.Department of NurseHigh School of Strategic PlanningDąbrowa GórniczaPoland

Personalised recommendations